Yasushi Goto
Overview
Explore the profile of Yasushi Goto including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
187
Citations
2512
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Saw S, Zhong W, Fu R, Li M, Goto Y, Fox S, et al.
Lung Cancer
. 2025 Jan;
200:108076.
PMID: 39799810
The peri-operative management of non-small cell lung cancer (NSCLC) in earlier stage disease has seen significant advances in recent years with the incorporation of immune checkpoint inhibitors and targeted therapy....
12.
Sands J, Ahn M, Lisberg A, Cho B, Blumenschein Jr G, Shum E, et al.
J Clin Oncol
. 2025 Jan;
:JCO2401349.
PMID: 39761483
Purpose: Datopotamab deruxtecan (Dato-DXd) is a trophoblast cell-surface antigen-2-directed antibody-drug conjugate with a highly potent topoisomerase I inhibitor payload. The TROPION-Lung05 phase II trial (ClinicalTrials.gov identifier: NCT04484142) evaluated the safety...
13.
Tateishi A, Okuma Y, Goto Y, Arakaki M, Igawa Y, Torasawa M, et al.
Anticancer Res
. 2024 Dec;
44(12):5501-5513.
PMID: 39626947
Background/aim: Thymic carcinoma is a rare cancer with poor prognosis in unresectable cases. Treatment efficacy of carboplatin+paclitaxel (CP), lenvatinib, S-1, and sunitinib remains uncertain, with some patients experiencing increased post-treatment...
14.
Akamatsu H, Koh Y, Nishio M, Goto Y, Hayashi H, Miura S, et al.
Lung Cancer
. 2024 Nov;
198:108017.
PMID: 39571250
Objectives: Programmed cell death ligand 1 (PD-L1) expression is widely used to predict the effectiveness of PD-(L)1 inhibitors despite its imperfection. Previous studies suggested the utilization of various serum biomarkers;...
15.
Hayashi H, Nishio M, Akamatsu H, Goto Y, Miura S, Gemma A, et al.
Cancer Res Commun
. 2024 Oct;
4(11):2858-2867.
PMID: 39392339
Purpose: Real-world, large-scale studies on the association between immune-related adverse events (irAE) and immune checkpoint inhibitor therapy effectiveness are limited. We evaluated overall survival (OS) and progression-free survival based on...
16.
Solomon B, Liu G, Felip E, Mok T, Soo R, Mazieres J, et al.
Future Oncol
. 2024 Oct;
20(40):3377-3387.
PMID: 39360949
What Is This Study About?: This is a summary of the results of an ongoing study called CROWN. In the CROWN study, researchers looked at the effects of two medicines...
17.
Igawa Y, Yoshida T, Makihara R, Torasawa M, Tateishi A, Matsumoto Y, et al.
Lung Cancer
. 2024 Sep;
196:107954.
PMID: 39303401
Objectives: Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK) inhibitor, causes distinct adverse events (AEs), including hyperlipidemia and central nervous system (CNS) disorders. Although dose modifications are recommended to manage these...
18.
Qi Z, Ha T, Feng W, Karnoub M, Pereira K, Shiga R, et al.
Arch Pathol Lab Med
. 2024 Sep;
PMID: 39299708
Context.—: Trastuzumab deruxtecan (T-DXd), a human epidermal growth factor receptor 2 (HER2)-targeted therapy, has demonstrated durable anticancer activity in patients with advanced, metastatic HER2 (also known as ERBB2)-mutant (HER2m) non-small...
19.
Goto Y
Gan To Kagaku Ryoho
. 2024 Aug;
51(8):791-794.
PMID: 39191705
Cancer treatment has made remarkable progress in recent years, particularly in the field of drug therapy. However, the high-cost of new drugs has led to active discussions about cost-effectiveness in...
20.
Yagishita S, Goto Y, Nishio M, Akamatsu H, Hayashi H, Miura S, et al.
JTO Clin Res Rep
. 2024 Aug;
5(7):100683.
PMID: 39091595
Introduction: This study validated real-world pharmacokinetic (PK) data using an established population PK (PopPK) model for atezolizumab in Japanese patients with NSCLC and explored the relationship between PK parameters, effectiveness,...